{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:12:31Z","timestamp":1790125951656,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40271-018-0312-x","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T01:24:14Z","timestamp":1526001854000},"page":"547-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States"],"prefix":"10.1007","volume":"11","author":[{"given":"Eileen Mack","family":"Thorley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi G.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle E.","family":"Carlozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"312_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","volume":"66","author":"T Foroud","year":"1999","unstructured":"Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington\u2019s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66:52\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"312_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S1474-4422(09)70183-8","volume":"8","author":"J Jankovic","year":"2009","unstructured":"Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844\u201356. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(09)70183-8\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"312_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204\u201316. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2014.24\n                    \n                  .","journal-title":"Nat Rev Neurol"},{"key":"312_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1399-0004.2011.01748.x","volume":"80","author":"AK Ho","year":"2011","unstructured":"Ho AK, Hocaoglu MB, European Huntington\u2019s Disease Network Quality of Life Working Group. Impact of Huntington\u2019s across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet. 2011;80:235\u20139. \n                    https:\/\/doi.org\/10.1111\/j.1399-0004.2011.01748.x\n                    \n                  .","journal-title":"Clin Genet"},{"key":"312_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/1359105312438109","volume":"18","author":"NE Carlozzi","year":"2013","unstructured":"Carlozzi NE, Tulsky DS. Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol. 2013;18:212\u201325. \n                    https:\/\/doi.org\/10.1177\/1359105312438109\n                    \n                  .","journal-title":"J Health Psychol"},{"key":"312_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC. Huntington\u2018s disease: a clinical review. Orphanet Rare Dis. 2010;5:1\u20138. \n                    https:\/\/doi.org\/10.1186\/1750-1172-5-40\n                    \n                  .","journal-title":"Orphanet Rare Dis"},{"key":"312_CR7","doi-asserted-by":"publisher","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"JM Burgunder","year":"2011","unstructured":"Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2018s disease. PLoS Curr. 2011;3:RRN1260. \n                    https:\/\/doi.org\/10.1371\/currents.RRN1260\n                    \n                  .","journal-title":"PLoS Curr"},{"key":"312_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JHD-170260","volume":"6","author":"NE Fritz","year":"2017","unstructured":"Fritz NE, Rao AK, Kegelmeyer D, Kloos A, Busse M, Hartel L, et al. Physical therapy and exercise interventions in Huntington\u2018s disease: a mixed methods systematic review. J Huntingtons Dis. 2017;6:217\u201335. \n                    https:\/\/doi.org\/10.3233\/JHD-170260\n                    \n                  .","journal-title":"J Huntingtons Dis"},{"key":"312_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/B978-0-444-52014-2.00002-1","volume":"100","author":"KE Anderson","year":"2011","unstructured":"Anderson KE. Huntington\u2019s disease. Handb Clin Neurol. 2011;100:15\u201324. \n                    https:\/\/doi.org\/10.1016\/B978-0-444-52014-2.00002-1\n                    \n                  .","journal-title":"Handb Clin Neurol"},{"key":"312_CR10","unstructured":"XENAZINE\u2122 (tetrabenazine) (prescribing information). Deerfield, IL: Lundbeck; 2017. Available at: \n                    http:\/\/www.lundbeck.com\/upload\/us\/files\/pdf\/Products\/Xenazine_PI_US_EN.pdf\n                    \n                  . Accessed April 2018."},{"key":"312_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366\u201372. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000198586.85250.13\n                    \n                  .","journal-title":"Neurology"},{"key":"312_CR12","unstructured":"AUSTEDO\u2122 (deutetrabenazine) tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2017. Available at: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208082s000lbl.pdf\n                    \n                  . Accessed April 2018."},{"key":"312_CR13","unstructured":"Teva Pharmaceutical Industries [press release]. Teva announces FDA approval of AUSTEDO\u2122 (deutetrabenazine) tablets for the treatment of chorea associated with Huntington\u2019s disease. 2017. \n                    http:\/\/www.tevapharm.com\/news\/teva_announces_fda_approval_of_austedo_deutetrabenazine_tablets_for_the_treatment_of_chorea_associated_with_huntington_s_disease_04_17.aspx\n                    \n                  . Accessed 2 May 2018."},{"key":"312_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79:597\u2013603. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e318263c443\n                    \n                  .","journal-title":"Neurology"},{"key":"312_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20:224\u201330. \n                    https:\/\/doi.org\/10.1002\/mds.20279\n                    \n                  .","journal-title":"Mov Disord"},{"key":"312_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1017\/S0317167100009082","volume":"35","author":"NF Bandstra","year":"2008","unstructured":"Bandstra NF, Camfield CS, Camfield PR. Stigma of epilepsy. Can J Neurol Sci. 2008;35:436\u201340.","journal-title":"Can J Neurol Sci"},{"key":"312_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/17423953060020030101","volume":"2","author":"N Grytten","year":"2006","unstructured":"Grytten N, Maseide P. \u2018When I am together with them I feel more ill\u2019. The stigma of multiple sclerosis experienced in social relationships. Chronic Illn. 2006;2:195\u2013208. \n                    https:\/\/doi.org\/10.1177\/17423953060020030101\n                    \n                  .","journal-title":"Chronic Illn"},{"key":"312_CR18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s11136-011-0062-x","volume":"21","author":"AV Aubeeluck","year":"2012","unstructured":"Aubeeluck AV, Buchanan H, Stupple EJ. \u2018All the burden on all the carers\u2019: exploring quality of life with family caregivers of Huntington\u2019s disease patients. Qual Life Res. 2012;21:1425\u201335. \n                    https:\/\/doi.org\/10.1007\/s11136-011-0062-x\n                    \n                  .","journal-title":"Qual Life Res"},{"key":"312_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00702-012-0787-x","volume":"119","author":"K Banaszkiewicz","year":"2012","unstructured":"Banaszkiewicz K, Sitek EJ, Rudzinska M, Soltan W, Slawek J, Szczudlik A. Huntington\u2019s disease from the patient, caregiver and physician\u2019s perspectives: three sides of the same coin? J Neural Transm (Vienna). 2012;119:1361\u20135. \n                    https:\/\/doi.org\/10.1007\/s00702-012-0787-x\n                    \n                  .","journal-title":"J Neural Transm (Vienna)"},{"key":"312_CR20","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.2196\/jmir.1549","volume":"12","author":"P Wicks","year":"2010","unstructured":"Wicks P, Massagli M, Frost J, Brownstein C, Okun S, Vaughan T, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res. 2010;12:e19. \n                    https:\/\/doi.org\/10.2196\/jmir.1549\n                    \n                  .","journal-title":"J Med Internet Res"},{"key":"312_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/WNL.0000000000001728","volume":"85","author":"JD Hixson","year":"2015","unstructured":"Hixson JD, Barnes D, Parko K, Durgin T, Van Bebber S, Graham A, et al. Patients optimizing epilepsy management via an online community: the POEM study. Neurology. 2015;85:129\u201336. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000001728\n                    \n                  .","journal-title":"Neurology"},{"key":"312_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/0471725153","volume-title":"Regression diagnostics: identifying influential data and sources of collinearity","author":"KE Belsley DA","year":"1980","unstructured":"DA Belsley KE, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: John Wiley; 1980."},{"key":"312_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277\u201388. \n                    https:\/\/doi.org\/10.1177\/1049732305276687\n                    \n                  .","journal-title":"Qual Health Res"},{"key":"312_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8852-5","author":"NE Carlozzi","year":"2018","unstructured":"Carlozzi NE, Boileau N, Perlmutter JS, et al. Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. J Neurol. 2018. \n                    https:\/\/doi.org\/10.1007\/s00415-018-8852-5\n                    \n                   (Epub 2018 Apr 23).","journal-title":"J Neurol"},{"key":"312_CR25","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","volume":"31","author":"I Shoulson","year":"1981","unstructured":"Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981;31:1333\u20135.","journal-title":"Neurology"},{"key":"312_CR26","unstructured":"Dubinsky R. The Huntington\u2019s disease Workgroup of Promoting Excellence in End-of-Life Care Total Functional Capacity Scale. Available at: \n                    http:\/\/promotingexcellence.growthhouse.org\/huntingtons\/monograph\/pe5670.html\n                    \n                  . Accessed April 2018."},{"key":"312_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1212\/WNL.54.2.452","volume":"54","author":"K Marder","year":"2000","unstructured":"Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington\u2019s disease. Huntington Study Group. Neurology. 2000;54:452\u20138.","journal-title":"Neurology"},{"key":"312_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/014572170102700613","volume":"27","author":"CE Golin","year":"2001","unstructured":"Golin CE, DiMatteo MR, Leake B, Duan N, Gelberg L. A diabetes-specific measure of patient desire to participate in medical decision making. Diabetes Educ. 2001;27:875\u201386. \n                    https:\/\/doi.org\/10.1177\/014572170102700613\n                    \n                  .","journal-title":"Diabetes Educ"},{"key":"312_CR29","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s11136-016-1386-3","volume":"25","author":"NE Carlozzi","year":"2016","unstructured":"Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res. 2016;25:2441\u201355. \n                    https:\/\/doi.org\/10.1007\/s11136-016-1386-3\n                    \n                  .","journal-title":"Qual Life Res"},{"key":"312_CR30","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s11136-016-1307-5","volume":"25","author":"NE Carlozzi","year":"2016","unstructured":"Carlozzi NE, Downing NR, Schilling SG, Lai JS, Goodnight SM, Miner JA, et al. The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Qual Life Res. 2016;25:2429\u201339. \n                    https:\/\/doi.org\/10.1007\/s11136-016-1307-5\n                    \n                  .","journal-title":"Qual Life Res"},{"key":"312_CR31","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/mds.27046","volume":"32","author":"NE Carlozzi","year":"2017","unstructured":"Carlozzi NE, Ready RE, Frank S, Cella D, Hahn EA, Goodnight SM, et al. Patient-reported outcomes in Huntington\u2019s disease: Quality of Life in Neurological Disorders (Neuro-QoL) and Huntington\u2019s disease Health-Related Quality of Life (HDQLIFE) physical function measures. Mov Disord. 2017;32:1096\u2013102. \n                    https:\/\/doi.org\/10.1002\/mds.27046\n                    \n                  .","journal-title":"Mov Disord"},{"key":"312_CR32","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.apmr.2011.01.025","volume":"92","author":"D Cella","year":"2011","unstructured":"Cella D, Nowinski C, Peterman A, Victorson D, Miller D, Lai JS, et al. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil. 2011;92:S28\u201336. \n                    https:\/\/doi.org\/10.1016\/j.apmr.2011.01.025\n                    \n                  .","journal-title":"Arch Phys Med Rehabil"},{"key":"312_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","volume":"21","author":"RC Gershon","year":"2012","unstructured":"Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21:475\u201386. \n                    https:\/\/doi.org\/10.1007\/s11136-011-9958-8\n                    \n                  .","journal-title":"Qual Life Res"},{"key":"312_CR34","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63:1179\u201394. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.011\n                    \n                  .","journal-title":"J Clin Epidemiol."},{"key":"312_CR35","unstructured":"HealthMeasures Neuro-QoL. 2017. \n                    http:\/\/www.healthmeasures.net\/explore-measurement-systems\/neuro-qol\n                    \n                  . Accessed 28 Sep 2017."},{"key":"312_CR36","first-page":"219","volume":"14","author":"D Craufurd","year":"2001","unstructured":"Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:219\u201326.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"312_CR37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mds.25500","volume":"28","author":"R Reilmann","year":"2013","unstructured":"Reilmann R. Pharmacological treatment of chorea in Huntington\u2019s disease\u2013good clinical practice versus evidence-based guideline. Mov Disord. 2013;28:1030\u20133. \n                    https:\/\/doi.org\/10.1002\/mds.25500\n                    \n                  .","journal-title":"Mov Disord"},{"key":"312_CR38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2522\/ptj.20070346","volume":"88","author":"ME Busse","year":"2008","unstructured":"Busse ME, Khalil H, Quinn L, Rosser AE. Physical therapy intervention for people with Huntington disease. Phys Ther. 2008;88:820\u201331. \n                    https:\/\/doi.org\/10.2522\/ptj.20070346\n                    \n                  .","journal-title":"Phys Ther"},{"key":"312_CR39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7916\/D8FJ2FD3","volume":"4","author":"E McCusker","year":"2014","unstructured":"McCusker E, Loy CT. The many facets of unawareness in huntington disease. Tremor Other Hyperkinet Mov (N Y). 2014;4:257. \n                    https:\/\/doi.org\/10.7916\/D8FJ2FD3\n                    \n                  .","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"312_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791\u2013801. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(09)70170-X\n                    \n                  .","journal-title":"Lancet Neurol."},{"key":"312_CR41","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391. \n                    https:\/\/doi.org\/10.1002\/mds.25075\n                    \n                  .","journal-title":"Mov Disord."},{"key":"312_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C et al","year":"2016","unstructured":"Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316:40\u201350. \n                    https:\/\/doi.org\/10.1001\/jama.2016.8655\n                    \n                  .","journal-title":"JAMA"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-018-0312-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T23:20:01Z","timestamp":1557530401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-018-0312-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["312"],"URL":"https:\/\/doi.org\/10.1007\/s40271-018-0312-x","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"11 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel. We thank the patients and caregivers who participated in this study, and Yue Liu, PhD (Chameleon Communications International with funding from Teva Pharmaceutical Industries) for editorial assistance in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EMT, PW, and CC are employees of PatientsLikeMe. The PatientsLikeMe Research Team has received research funding (including conference support and consulting fees) from AbbVie, Accorda, Actelion, Alexion, Amgen, AstraZeneca, Avanir, Biogen, Boehringer Ingelheim, Celgene, EMD, Genentech, Genzyme, Janssen, Johnson & Johnson, Merck, Neuraltus, Novartis, Otsuka, Permobil, Pfizer, Sanofi, Shire, Takeda, Teva, and UCB. The PatientsLikeMe Research and Development Team has received research grant funding from Kaiser Permanente, the Robert Wood Johnson Foundation, Sage Bionetworks, The AKU Society, and the University of Maryland. PW also holds stock options in the company. He is an associate editor at the Journal of Medical Internet Research and is on the Editorial Boards of the BMJ, BMC Medicine, and Digital Biomarkers. He has received speaker fees from Bayer and honoraria from Roche, ARISLA, AMIA, IMI, PSI, and the BMJ. RGI and SKG are employees of Teva Pharmaceutical Industries. VA was an employee of Teva Pharmaceuticals Industries at the time of the study. KEA: Scientific Advisor: North American study Co-Principal Investigator for LEGATO-HD, Global Principal Investigator for AIM-TD, and Global Co-Principal Investigator for ARM-TD. Site Principal Investigator for Pride-HD, First-HD, ARC-HD: Teva. Scientific Advisor, Site Principal Investigator for ENROLL-HD: CHDI Foundation. Scientific Advisor: Prana. Site Principal Investigator: Vaccinex. Consultant to the NeuroNext 105 study: Azevan, salary support from the Griffin Foundation. She has also received honoraria from Vindico Medical Education. NEC is an Associate Professor at the University of Michigan. She currently has research grants from the NIH, the Craig H. Neilsen Foundation and Teva Pharmaceuticals; she is also supported as a co-investigator by grant funding from the NIH and CHDI. She provides patient reported outcome measurement selection and application consultation for Teva Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed by the New England Institutional Review Board (NEIRB) and designated a minimal-risk study; therefore, it was exempted from further review. Participants were provided with an informed consent form (approved by the NEIRB), which had to be understood and agreed upon prior to any data collection. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}